Please try another search
Shire-NPS Pharmaceuticals, Inc., a biopharmaceutical company, provides therapeutic products for the treatment of gastrointestinal and endocrine disorders. The company offers Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support in the United States; and Revestive for the treatment of adult patients with SBS in the European Union. Its products also include Gattex/Revestive in pediatric SBS; Natpara, a bioengineered replica of human parathyroid hormone to control hypocalcemia in patients with hypoparathyroidism; and Natpar to treat hypoparathyroidism, as well as NPSP795, a calcilytic agent for treating disorders involving increased calcium receptor activity. In addition, the company offers various royalty-based products, such as Sensipar and Mimpara for the treatment of primary and secondary hyperparathyroidism; Sensipa for treating hypercalcemia in parathyroid cancer; REGPARA for the treatment of secondary hyperparathyroidism; and NUCYNTA and Nucynta ER for treating acute pain and chronic pain. The company was formerly known as NPS Pharmaceuticals, Inc. and changed its name to Shire-NPS Pharmaceuticals, Inc. in June 2017. Shire-NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey. As of February 21, 2015, The company operates as a subsidiary of Shire Pharmaceutical Holdings Ireland Limited.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review